{
    "organizations": [],
    "uuid": "d2005291e685d9bdcefef844ba94578d33bfa528",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/13/business-wire-sage-therapeutics-to-report-fourth-quarter-and-full-year-2017-financial-results-on-thursday-february-22-2018.html",
    "ord_in_thread": 0,
    "title": "Sage Therapeutics to Report Fourth Quarter Full Year Financial Results on Thursday, February 22, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, February 22, 2018 at 8:00 A.M. ET to report its fourth quarter and full year 2017 financial results and to discuss recent business updates.\nThe live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com . The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 6272049. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.\nAbout Sage Therapeutics\nSage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com .\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180213005284/en/\nSage Therapeutics\nInvestor Contact:\nPaul Cox, 617-299-8377\npaul.cox@sagerx.com\nor\nMedia Contact:\nMaureen L. Suda, 585-355-1134\nmaureen.suda@sagerx.com\nSource: Sage Therapeutics",
    "published": "2018-02-13T14:30:00.000+02:00",
    "crawled": "2018-02-13T14:25:58.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cambridge",
        "business",
        "wire",
        "sage",
        "therapeutic",
        "nasdaq",
        "sage",
        "biopharmaceutical",
        "company",
        "developing",
        "novel",
        "medicine",
        "treat",
        "central",
        "nervous",
        "system",
        "cns",
        "disorder",
        "today",
        "announced",
        "company",
        "host",
        "conference",
        "call",
        "live",
        "webcast",
        "thursday",
        "february",
        "et",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "discus",
        "recent",
        "business",
        "update",
        "live",
        "webcast",
        "accessed",
        "investor",
        "page",
        "sage",
        "website",
        "conference",
        "call",
        "accessed",
        "dialing",
        "domestic",
        "international",
        "using",
        "conference",
        "id",
        "replay",
        "webcast",
        "available",
        "sage",
        "website",
        "approximately",
        "two",
        "hour",
        "completion",
        "event",
        "archived",
        "day",
        "sage",
        "therapeutic",
        "sage",
        "therapeutic",
        "biopharmaceutical",
        "company",
        "committed",
        "developing",
        "novel",
        "medicine",
        "transform",
        "life",
        "patient",
        "central",
        "nervous",
        "system",
        "cns",
        "disorder",
        "sage",
        "portfolio",
        "novel",
        "product",
        "candidate",
        "targeting",
        "critical",
        "cns",
        "receptor",
        "system",
        "gaba",
        "nmda",
        "sage",
        "lead",
        "program",
        "proprietary",
        "iv",
        "formulation",
        "brexanolone",
        "completed",
        "two",
        "phase",
        "clinical",
        "trial",
        "postpartum",
        "depression",
        "sage",
        "developing",
        "next",
        "generation",
        "modulators",
        "including",
        "various",
        "cns",
        "disorder",
        "information",
        "please",
        "visit",
        "view",
        "source",
        "version",
        "http",
        "sage",
        "therapeutic",
        "investor",
        "contact",
        "paul",
        "cox",
        "medium",
        "contact",
        "maureen",
        "suda",
        "source",
        "sage",
        "therapeutic"
    ]
}